FINWIRES · TerminalLIVE
FINWIRES

Allied Critical Metals股价上涨7%，获4000万美元融资

-- Allied Critical Metals (ACM.CN) 周五宣布，公司将通过私募配售股票筹集 2500 万美元，同时还将获得 1500 万美元的项目融资。 此次私募配售将面向一位现有投资者和一位新投资者，发行价为每股 2.05 美元。现有投资者将为此次发行提供担保，首期 1000 万美元的募集将立即完成，剩余的 1500 万美元将于 7 月 17 日前完成。 现有投资者还将为 Allied 的 Villa Verde 试点项目提供 1500 万美元，并已签署一份承购协议，承诺在 2026 年以每公吨 1000 美元的最低价格购买该项目 50% 的钨精矿。公司表示，目前钨的价格已超过每公吨 3000 美元。Allied Critical 计划于今年第四季度实现该工厂的首批钨精矿生产。 声明补充道，此次私募所得款项将用于开发葡萄牙的博拉利亚钨矿项目和维拉维德工厂。 “我们很高兴地宣布，我们已达成一项变革性的融资方案，该方案不仅将加快钨精矿的生产，还将巩固我们的资产负债表。维拉维德试验工厂正按计划推进，将于今年投产，为全球市场提供急需的钨精矿，”首席执行官罗伊·邦内尔表示。 “获得两家战略投资者的支持，验证了我们加快钨精矿生产的战略，并确保我们在博拉利亚钨矿项目矿山建设之前资金充足，这两件事对我们公司而言都是重要的里程碑。” Allied Critical的股票在加拿大证券交易所最新上涨0.14美元，至2.08美元。

Price: $2.09, Change: $+0.15, Percent Change: +7.73%

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB